Neurotoxicity Clinical Trial
Official title:
Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
The purpose of this study is to determine whether Monosialotetrahexosylganglioside sodium injection can relieve the neurotoxicity caused by oxaliplatin in GI cancer.
Oxaliplatin is widely used in GI cancer. Neutropenia and neurotoxicity are the most common adverse effects of oxaliplatin which even result in discontinue of chemotherapy, especially for patients suffered from heavily acute neurotoxicity.The continuous sense and/or motor abnormal reduce the quality of life. To date, there is no a drug to treat oxaliplatin induced neurotoxicity. Monosialotetrahexosylganglioside(GM) is a component of membrane of nerve cells. Previous phase II clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity (OIN). But it did not investigated for curing OIN in randomized control trial. A phase III trial is needed to investigate the effect and safety of monosialotetrahexosylganglioside Sodium Injection for treatment OIN at GI cancer. Investigators design this randomized phase III placebo-controlled trail to identify the effect of monosialotetrahexosylganglioside sodium injection as a treatment agent for OIN. Investigators found 2.5% patients of grade 2 or more serious OIN would relieve with 3 months(data not published). Investigators assume monosialotetrahexosylganglioside can reduce neurotoxicity by 30%. At the level of power 0.8, the sample size is 160 with 10% dropout. If there is no dropout, the trial will be terminated at 144 events occur.The board of Tianjin cancer hospital has permitted the trial and will monitor the whole process of this study. All data will be submitted to the department of clinic trials at Tianjin cancer hospital.The statistics specialist is participating this design and will afford help for data analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
| Completed |
NCT01399372 -
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
| Completed |
NCT00775645 -
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT00884767 -
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT03330964 -
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
|
N/A | |
| Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
| Completed |
NCT01417507 -
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
|
N/A | |
| Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 | |
| Completed |
NCT00365768 -
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
|
Phase 2 | |
| Withdrawn |
NCT00734773 -
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
|
Phase 0 | |
| Completed |
NCT00305799 -
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
|
N/A | |
| Completed |
NCT00018967 -
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
|
N/A | |
| Active, not recruiting |
NCT00978458 -
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
|
Phase 3 | |
| Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
| Not yet recruiting |
NCT05798884 -
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
|
N/A | |
| Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
| Completed |
NCT00755313 -
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
|
N/A | |
| Completed |
NCT00369564 -
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
|
Phase 3 | |
| Completed |
NCT00078845 -
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
|
Phase 2 |